although
cellmedi
immun
crucial
control
erad
infect
mani
virus
antibodi
pivot
prevent
modul
infect
even
earli
phase
infect
level
antibodi
induc
activ
immun
administ
passiv
immun
low
antibodi
reduc
size
infect
inoculum
neutral
elimin
virion
first
round
replic
provid
suffici
transient
protect
cellular
arm
immun
respons
respond
prolifer
deploy
effector
cell
requir
elimin
virusinfect
cell
data
indic
model
applic
infect
simian
immunodefici
viru
siv
chimer
simianhuman
immunodefici
viru
shiv
despit
extens
data
support
gener
import
antibodi
prevent
viru
infect
fig
percept
role
antibodi
prevent
infect
vari
markedli
past
year
opinion
rang
wildli
optimist
view
held
late
antibodi
would
suffici
protect
infect
bleakest
predict
primari
isol
resist
antibodymedi
neutral
vaccin
would
ever
abl
induc
antibodi
suffici
broad
potent
provid
protect
mani
passiv
immun
experi
variou
experiment
model
howev
repeatedli
establish
antibodi
provid
steril
immun
ref
addit
passiv
immun
experi
indic
antibodi
reduc
size
infecti
inoculum
allow
develop
effect
cellular
humor
immun
respons
breakthrough
viru
studi
provid
convinc
data
experiment
model
test
neutral
antibodi
appropri
specif
present
suffici
concentr
correl
immun
protect
even
human
studi
indic
antibodi
transfer
across
placenta
might
protect
transmiss
infect
pregnant
women
infant
although
studi
controversi
issu
human
requir
antibodi
protect
viru
infect
mani
mechan
fig
main
mode
protect
induc
antivir
vaccin
seem
mediat
neutral
antibodi
past
year
pendulum
opinion
vaccin
field
swung
two
extrem
initi
favour
induct
antibodi
subsequ
favour
induct
cellmedi
immun
respons
present
consensu
seem
induct
humor
cellular
immun
vaccin
requir
achiev
maximum
protect
one
obstacl
develop
effect
vaccin
difficulti
induc
broadli
reactiv
potent
antibodi
protect
function
defin
epitop
design
immunogen
induc
antibodi
one
main
challeng
confront
vaccin
field
induct
immun
immunogen
activ
expand
endogen
immun
repertoir
elicit
antibodi
cellmedi
immun
well
immunolog
memori
might
last
decad
immun
provid
rapidli
transfer
immunoglobulin
maxim
activ
last
week
wane
due
catabol
destruct
yet
shown
block
late
stage
viru
life
cycl
therefor
antibodi
prevent
primari
uncoat
viru
cytoplasm
transcript
step
nucleu
viru
assembl
bud
cell
membran
viru
exit
cell
addit
mechan
antibodi
mediat
protect
includ
aggreg
viru
particl
reduc
size
inoculum
render
virion
suscept
phagocytosi
destruct
lysi
envelop
virus
bind
virion
initi
complement
cascad
antibodi
might
also
attack
virusinfect
cell
exampl
antibodydepend
cellmedi
cytotox
adcc
welldocu
antivir
mechan
control
viru
infect
shown
affect
cell
given
rediscov
import
antibodi
prevent
infect
necessari
reexamin
question
antibodi
induc
might
achiev
consist
correl
immun
protect
viral
gener
term
abil
antibodi
reduc
infect
viru
particl
interf
one
sever
differ
step
viru
life
cycl
exampl
antibodi
bind
molecul
surfac
virion
prevent
interact
cellsurfac
lectin
variou
receptor
case
type
inhibit
attribut
carbohydratespecif
antibodi
target
viru
glycoprotein
antibodi
target
differ
adhes
molecul
antibodi
specif
variou
region
domain
epitop
locat
bridg
sheet
creat
expos
interact
loop
see
fig
box
addit
mani
postattach
mechan
document
exampl
provid
antibodi
prevent
fusion
viru
cell
membran
case
human
monoclon
antibodi
describ
later
might
antibodi
prevent
either
format
coiledcoil
form
fusion
viru
cell
membran
antibodi
also
mediat
postfus
neutral
mani
virus
although
sever
human
monoclon
antibodi
specif
produc
sever
epitop
within
defin
fig
tabl
box
howev
small
minor
antibodi
neutral
activ
one
human
monoclon
antibodi
shown
broad
neutral
activ
divers
primari
isol
monoclon
antibodi
recogn
core
epitop
six
amino
acid
within
rel
conserv
linear
sequenc
neqelleldkwaslwn
ectodomain
near
transmembran
region
molecul
two
addit
human
monoclon
antibodi
specif
transmembran
proxim
region
region
immedi
carboxytermin
epitop
also
broad
neutral
activ
epitop
region
poorli
expos
infect
presenc
neutral
antibodi
emphasi
place
identifi
antibodi
neutral
pathogen
induc
polyclon
antibodi
respons
wide
array
epitop
differ
viral
protein
studi
polyclon
sera
help
identifi
specif
antibodi
associ
protect
studi
human
monoclon
antibodi
clearli
defin
epitop
locat
two
envelop
glycoprotein
induc
neutral
antibodi
natur
infect
tabl
mediat
protect
infect
passiv
immun
studi
induct
antibodi
epitop
might
ultim
use
defens
shield
infect
howev
epitop
present
challeng
vaccin
design
figur
diagram
structur
envelop
glycoprotein
molecul
locat
variabl
region
mark
box
glycosyl
site
contain
high
mannosetyp
andor
hybridtyp
oligosaccharid
structur
indic
branch
structur
glycosyl
site
contain
complextyp
oligosaccharid
structur
indic
ushap
branch
epitop
induc
neutral
antibodi
highlight
colour
includ
highli
conform
domain
key
epitop
highlight
yellow
epitop
green
epitop
compos
mannos
residu
purpl
loop
orang
loop
blue
reproduc
permiss
ref
american
societi
biochemistri
molecular
biolog
wwwnaturecomreviewsimmunol
r
e
v
e
w
antibodi
recogn
epitop
access
chang
cours
infect
antigen
determin
exposur
occur
limit
period
viru
infect
character
transit
epitop
term
also
appli
envelop
epitop
see
later
surfac
intact
viru
particl
membran
virusinfect
cell
studi
show
exposur
epitop
alter
chang
envelop
monoclon
antibodi
bind
poorli
virion
yet
neutral
viru
indic
monoclon
transmembraneproxim
region
poorli
expos
surfac
viru
thought
transit
epitop
expos
brief
period
time
conform
chang
occur
lead
fusion
viru
cell
membran
aminotermin
carboxytermin
heptad
repeat
region
repeat
motif
region
form
leucin
zipper
involv
format
coiledcoil
form
conform
chang
induc
interact
chemokin
receptor
fusion
peptid
aminotermin
region
expos
format
coiledcoil
form
region
insert
membran
target
cell
result
fusion
viru
cell
membran
three
molecul
noncoval
link
trimer
form
heterooligomer
spike
surfac
viru
particl
differ
region
interact
chemokin
receptor
found
surfac
target
cell
interact
lead
seri
conform
chang
subsequ
allow
conform
chang
lead
format
coiledcoil
form
exposur
fusion
peptid
domain
compos
sever
part
molecul
form
bind
pocket
region
fit
bridg
sheet
compos
four
antiparallel
stem
region
region
involv
bind
chemokin
receptor
trigger
subsequ
conform
chang
region
form
expos
bind
known
epitop
loop
highli
variabl
region
proxim
part
bridg
sheet
loop
togeth
loop
seem
shield
partial
bridg
sheet
part
loop
conform
chang
induc
loop
semiconserv
region
structur
constrain
requisit
particip
viru
infect
loop
interact
chemokin
receptor
surfac
target
cell
data
indic
antibodi
membraneproxim
region
might
prevent
infect
block
either
format
coiledcoil
form
chang
lead
fusion
viru
cell
membran
howev
region
especi
core
epitop
recogn
monoclon
antibodi
eldkwa
seem
poorli
immunogen
antibodi
specif
epitop
occur
infrequ
individu
moreov
experiment
immunogen
consist
epitop
insert
either
influenza
viru
haemagglutinin
antigen
hepat
b
viru
surfac
antigen
escherichia
coli
maie
protein
fail
elicit
antisera
neutral
activ
primari
isol
therefor
interest
epitop
seem
requir
particular
molecular
context
context
might
reduc
effici
present
immun
system
human
monoclon
antibodi
clone
epitop
span
disulphid
bond
immunodomin
loop
ectodomain
gcsgklictt
also
shown
neutral
primari
isol
interestingli
human
monoclon
antibodi
monoclon
antibodi
recogn
epitop
offset
amino
acid
upstream
clone
epitop
neutral
capac
antibodi
domain
domain
molecul
fig
box
highli
conserv
complex
conformationdepend
region
definit
respons
interact
viru
envelop
molecul
surfac
target
cell
interact
pivot
process
infect
assum
antibodi
specif
would
particularli
effect
block
infect
inde
mani
monoclon
antibodi
region
neutral
tcelllineadapt
virus
howev
monoclon
antibodi
exemplifi
monoclon
antibodi
neutral
primari
isol
reason
still
well
understood
except
human
monoclon
antibodi
construct
use
recombin
technolog
bone
marrow
donor
monoclon
antibodi
except
broad
activ
primari
isol
therebi
confirm
crucial
role
infect
given
complex
pauciti
monoclon
antibodi
neutral
activ
design
immunogen
give
rise
neutral
antibodi
specif
epitop
challeng
addit
observ
complic
rational
elicit
antibodi
antibodi
recent
shown
interfer
process
antigenpres
cell
block
subsequ
present
epitop
envelopespecif
helper
cell
find
indic
induct
antibodi
specif
even
immunodomin
antigen
determin
within
complex
mixtur
protein
whole
viru
preferenti
stimul
strong
immun
respons
tcelllineadapt
viru
hiv
strain
adapt
growth
tissu
cultur
transform
cell
wwwnaturecomreviewsimmunol
r
e
v
e
w
antibodi
mediat
neutral
given
locat
epitop
surfac
known
involv
viru
attach
fusion
variabl
loop
fig
box
long
recogn
contain
epitop
induc
potent
neutral
antibodi
howev
sceptic
persist
concern
protect
valu
antibodi
variabl
region
antibodi
thought
isol
specif
variabl
natur
region
thought
inevit
allow
escap
effect
antibodi
antibodi
region
sceptic
use
antibodi
might
warrant
although
studi
polyclon
antibodi
specif
region
show
potent
antivir
neutral
activ
broad
neutral
activ
primari
virus
gener
properti
antibodi
shown
inabl
sever
rodent
human
monoclon
antibodi
monoclon
antibodi
neutral
panel
tcelllineadapt
primari
isol
k
gorni
unpublish
observ
seem
due
fact
region
vari
sequenc
also
length
due
insert
delet
alter
elimin
conserv
element
broadli
neutral
antibodi
could
target
given
virus
lack
region
variabl
loop
capabl
replic
region
essenti
infect
therefor
rel
unconstrain
term
mutat
therefor
despit
fact
region
viru
envelop
carri
import
function
mediat
interact
within
trimer
shield
region
around
bridg
sheet
respons
interact
chemokin
receptor
loop
improb
target
vaccin
fact
specif
delet
vaccin
construct
provid
better
access
neutral
epitop
near
coreceptor
bind
site
contrast
variabl
natur
region
stem
loop
rel
well
conserv
involv
format
chemokinereceptorbind
site
interact
ref
indic
stem
crucial
role
make
potenti
valuabl
target
antibodi
howev
antibodi
specif
region
yet
describ
indic
site
poorli
immunogen
andor
poorli
transient
expos
antibodi
loop
similar
loop
aminoacid
sequenc
loop
variabl
distinct
structur
characterist
function
due
variabl
natur
antibodi
similar
antibodi
isol
specif
isolatespecif
monoclon
antibodi
neutral
activ
could
potenti
inhibit
develop
effect
cellular
immun
respons
viru
envelop
note
antibodi
specif
epitop
effect
antibodi
found
individu
react
better
complex
solubl
conform
chang
induc
solubl
creat
expos
epitop
region
recogn
monoclon
antibodi
map
region
involv
bind
chemokin
receptor
recogn
epitop
form
stem
region
sever
human
monoclon
antibodi
identifi
show
relev
epitop
immunogen
least
subset
infect
individu
one
monoclon
antibodi
specif
epitop
monoclon
antibodi
particularli
use
crystallograph
studi
ref
surprisingli
monoclon
antibodi
monoclon
antibodi
epitop
complet
igg
form
neutral
primari
isol
test
interestingli
antigenbind
fragment
fab
singlechain
fragment
monoclon
antibodi
neutral
function
inabl
whole
igg
monoclon
antibodi
neutral
explain
steric
hindranc
given
distanc
epitop
target
cell
membran
molecular
model
seem
small
accommod
entir
igg
molecul
observ
confirm
physic
constraint
antibodi
access
epitop
preclud
use
antibodi
epitop
barrier
infect
antibodi
carbohydr
epitop
given
mass
compos
carbohydr
moieti
perhap
surpris
antibodi
carbohydr
neutral
activ
ref
best
studi
neutral
carbohydratespecif
antibodi
human
origin
monoclon
antibodi
target
cluster
carbohydr
moieti
fig
monoclon
antibodi
broad
neutral
activ
tcelllineadapt
primari
isol
ref
crystallograph
studi
reveal
unusu
structur
allow
multival
interact
conserv
cluster
oligomannosetyp
sugar
howev
extrem
unusu
configur
monoclon
antibodi
poor
immunogen
epitop
recogn
monoclon
antibodi
ref
rais
sever
question
probabl
vaccin
could
regularli
elicit
antibodi
could
immunogen
design
mimic
uniqu
cluster
oligomannos
residu
target
mechan
monoclon
establish
yonezawa
et
al
show
infect
retain
loop
viru
replac
amino
acid
region
includ
domain
structur
homolog
loop
virus
data
reveal
mechan
viru
envelop
interact
chemokin
receptor
support
crucial
role
region
viru
infect
explain
must
mark
conserv
loop
provid
rational
antibodi
conserv
motif
highli
crossreact
antibodi
mainli
produc
earli
infect
brief
immun
protocol
moreov
monoclon
antibodi
produc
infect
individu
select
use
linear
peptid
littl
neutral
activ
primari
isol
despit
broad
immunochem
crossreact
howev
addit
isolatespecif
antibodi
broadli
reactiv
antibodi
potent
neutral
activ
describ
polyclon
monoclon
antibodi
conform
sensit
rather
specif
linear
epitop
loop
broadli
reactiv
neutral
monoclon
antibodi
neutral
larg
proport
clade
b
primari
isol
also
shown
neutral
virus
clade
f
definit
must
share
crossreact
epitop
antibodi
broad
specif
function
activ
similar
monoclon
antibodi
probabl
produc
later
infect
result
somat
hypermut
variableregion
immunoglobulin
gene
occur
matur
humor
immun
respons
given
antigen
appar
requir
prolong
antigen
stimul
induc
broadli
reactiv
antibodi
challeng
problem
term
design
practic
vaccin
strategi
induc
broadli
reactiv
protect
antibodi
far
clinic
vaccin
trial
address
whether
longer
immun
regimen
induc
broadli
reactiv
neutral
antibodi
gener
highli
crossreact
antibodi
particular
surpris
crossreact
antibodi
explain
basi
structur
function
characterist
loop
therefor
despit
design
third
variabl
domain
unlik
region
loop
actual
semiconserv
region
mani
constant
featur
includ
fix
size
amino
acid
conserv
type
ii
turn
tip
disulphid
bond
base
net
posit
charg
structur
constraint
impos
function
requir
loop
interact
chemokin
receptor
viru
infect
inde
delet
loop
result
noninfecti
virion
conserv
natur
loop
explain
homolog
structur
natur
ligand
viru
coreceptor
reveal
nuclear
magnet
reson
nmr
spectroscopi
peptid
complex
fragment
two
monoclon
antibodi
preferenti
neutral
ccchemokin
receptor
tropic
cxcchemokin
receptor
tropic
virus
virus
respect
structur
studi
show
altern
conform
homolog
structur
ccchemokin
macrophag
inflammatori
protein
rant
cxcchemokin
stromalcellderiv
factor
respect
fig
function
homolog
loop
viru
somat
hypermut
process
antigenactiv
b
cell
germin
centr
mutat
rearrang
immunoglobulin
gene
b
cell
select
express
best
mutat
basi
abil
cellsurfac
immunoglobulin
bind
antigen
b
figur
altern
conform
loop
mimic
structur
chemokin
spacefil
diagram
cxcchemokin
ligand
also
known
stromalcellderiv
factor
structur
shown
ribbon
diagram
structur
loop
defin
nuclear
magnet
reson
nmr
analysi
complex
mous
monoclon
antibodi
shown
red
superimpos
shown
green
b
spacefil
diagram
ccchemokin
ligand
also
known
rant
structur
shown
ribbon
diagram
structur
loop
defin
nmr
analysi
complex
human
monoclon
antibodi
shown
purpl
superimpos
shown
green
imag
courtesi
schapira
wwwnaturecomreviewsimmunol
r
e
v
e
w
charg
region
viru
envelop
key
ligandreceptor
interact
challeng
induc
broadli
neutral
antibodi
immun
lie
design
antigen
present
immunogen
conform
correct
loop
present
formul
dose
schedul
allow
optim
matur
antibodi
respons
although
mani
human
monoclon
antibodi
variou
epitop
identifi
neutral
primari
isol
epitop
recogn
monoclon
antibodi
care
dissect
might
addit
protect
epitop
yet
identifi
present
avail
panel
monoclon
antibodi
epitop
might
form
quaternari
structur
result
interact
monomer
envelop
subunit
form
trimer
surfac
intact
virion
asyetundefin
epitop
might
immunogen
subset
individu
might
compos
structur
appear
isol
might
predomin
less
well
studi
viru
subtyp
final
new
epitop
might
consist
transit
epitop
andor
molecular
region
poorli
repres
variou
screen
regimen
use
select
monoclon
antibodi
defin
addit
epitop
induc
neutral
antibodi
individu
provid
addit
scaffold
model
candid
vaccin
envelop
glycoprotein
contain
larg
number
bcell
epitop
current
vaccin
protocol
induc
antibodi
mani
epitop
rather
focus
immun
respons
epitop
induc
protect
antibodi
epitop
near
disulphid
loop
ectodomain
exampl
immunodomin
give
rise
antibodi
gener
neutral
given
sever
neutral
epitop
alreadi
identifi
would
advantag
direct
antibodi
respons
protect
epitop
sever
approach
use
focu
immun
respons
one
epitop
exampl
limit
envelop
deglycosyl
delet
loop
seem
creat
immunogen
augment
level
neutral
antibodi
improv
exposur
andor
immunogen
neutral
epitop
contrari
approachhyperglycosyl
studi
abrog
immunogen
one
key
envelop
epitop
approach
includ
use
singl
multiplechain
peptid
induc
antibodi
specif
region
envelop
sever
addit
new
approach
recent
propos
design
vaccin
immunogen
one
known
revers
immunolog
identifi
peptid
ligand
bound
mhc
molecul
tcell
receptor
immunoglobulin
defin
peptid
immunogen
studi
also
prompt
reexamin
data
underli
longstand
dogma
antibodi
isol
specif
neutral
primari
isol
exampl
know
wherea
isolatespecif
antibodi
produc
earli
infect
immun
broadli
reactiv
antibodi
characterist
matur
immun
respons
similarli
conclus
antibodi
ineffect
neutral
primari
isol
base
ineffici
deplet
antibodi
sera
linear
peptid
process
would
fail
effect
remov
antibodi
specif
conformationsensit
epitop
moreov
care
review
earli
studi
well
recent
data
publish
sever
group
show
epitop
loop
cryptic
least
partial
display
surfac
viru
particl
cell
monoclon
antibodi
neutral
well
virus
summari
studi
show
conserv
conform
loop
crucial
function
pattern
charg
residu
tip
loop
import
coreceptor
bind
region
loop
chemokin
crucial
interact
chemokin
receptor
discontinu
element
strongli
support
hypothesi
conform
pattern
revers
immunolog
process
design
vaccin
immunogen
studi
antibodi
induc
antigen
posit
neutral
serumviru
pair
denot
green
box
absenc
neutral
denot
blue
box
antibodi
preferenti
neutral
viru
subtyp
infect
patient
neutral
sera
subject
infect
subtyp
b
c
ae
would
preferenti
neutral
virus
subtyp
shown
part
fact
pattern
approxim
part
b
achiev
sever
studi
indic
littl
correl
neutral
activ
patient
serum
genotyp
viru
infect
patient
epitop
discuss
earlier
could
serv
target
neutral
antibodi
found
constant
region
viru
envelop
other
local
variabl
region
although
variabl
epitop
region
retain
conserv
element
present
data
indic
least
two
conform
exist
therefor
induc
antibodi
neutral
epitop
variabl
region
polyval
vaccin
requir
requir
polyval
vaccin
antigen
variabl
pathogen
well
establish
given
requir
multiplestrainbas
vaccin
organ
polio
viru
influenza
viru
streptococcu
pneumonia
vaccin
extens
research
necessari
identifi
mani
strain
requir
maximum
protect
case
influenza
viru
choic
vaccin
strain
ongo
concern
antigen
natur
organ
constantli
chang
similar
challeng
probabl
face
vaccin
field
highli
unlik
singl
construct
protect
subtyp
given
continu
evolut
viru
spread
subtyp
throughout
world
question
choos
mani
strain
need
repres
vaccin
give
maximum
protect
initi
approach
design
polyval
vaccin
base
choos
virus
repres
genet
defin
clade
subtyp
clade
defin
basi
nucleotid
sequenc
genom
includ
gene
encod
envelop
glycoprotein
far
three
group
identifi
n
within
group
main
group
infect
patient
worldwid
nine
clade
circul
recombin
form
identifi
sever
studi
shown
sera
infect
individu
might
neutral
sever
primari
isol
variou
clade
similar
potenc
except
clade
b
e
show
distinct
antigen
differ
seem
particular
prefer
sera
patient
infect
one
clade
neutral
virus
clade
diagramat
represent
shown
fig
similarli
studi
human
monoclon
antibodi
come
cladebinfect
individu
list
tabl
show
compar
potenc
neutral
mani
virus
variou
clade
data
rais
import
question
relev
genotyp
classif
vaccin
design
therefor
addit
genotyp
classif
approach
use
identifi
repres
virus
inclus
polyval
vaccin
bioinformat
techniqu
use
search
sequenc
databas
common
epitop
could
induc
crossclad
immun
relat
techniqu
use
identifi
construct
envelop
protein
antigen
similar
present
circul
strain
ancestr
virus
might
effect
elicit
crossreact
immun
respons
third
approach
base
immunolog
studi
recogn
immun
system
given
number
monoclon
antibodi
neutral
activ
describ
surpris
similar
strategi
use
determin
bcell
epitop
recogn
exampl
zwick
et
al
identifi
peptid
mimotop
epitop
recogn
monoclon
antibodi
peptid
homodim
activ
depend
intact
disulphid
bridg
join
polypeptid
chain
disappointingli
vaccin
construct
synthet
peptid
conjug
two
differ
carrier
fail
elicit
signific
crossreact
antibodi
broadli
neutral
human
monoclon
antibodi
also
screen
random
phage
librari
peptid
identifi
sequenc
contain
gpxrmotif
characterist
tip
loop
one
peptid
identifi
bind
strongli
monoclon
antibodi
conjug
carrier
use
immun
rabbit
sera
three
four
rabbit
show
neutral
activ
two
five
variant
test
result
indic
least
epitop
use
mimotop
defin
use
monoclon
antibodi
might
lead
design
immunogen
induc
neutral
antibodi
although
simpl
task
design
mimotop
feasibl
structur
sever
human
monoclon
antibodi
broad
neutral
activ
studi
nmr
xray
crystallograph
analys
inform
epitop
monoclon
antibodi
recogn
key
featur
combin
site
use
design
immunogen
induc
similar
antibodi
potenti
promis
approach
suggest
result
obtain
mimotopebas
vaccin
develop
human
tcell
leukaemia
viru
type
measl
coronaviru
herp
simplex
viru
might
use
target
antibodi
respons
neutral
epitop
rather
immun
nativ
molecul
construct
base
whole
molecul
bear
mani
neutral
nonneutr
epitop
neutral
epitop
conform
sensit
indic
peptid
immunogen
might
present
optim
shape
immun
system
loop
consid
semiconserv
region
due
structur
conform
conserv
might
therefor
valuabl
target
vaccin
envelop
constant
region
induct
neutral
antibodi
increas
emphasi
place
design
immunogen
induc
antibodi
specif
variou
constant
variabl
domain
interact
chemokin
receptor
increas
emphasi
place
induc
antibodi
interfer
requir
conform
chang
viru
divers
pose
challeng
vaccin
develop
might
address
recogn
need
polyval
vaccin
identifi
repres
virus
includ
vaccin
recogn
despit
viru
divers
constant
featur
viru
envelop
requir
interact
receptor
coreceptor
envelop
glycoprotein
attempt
classifi
strain
term
immunolog
characterist
cluster
analysi
immunochem
neutral
data
polyclon
monoclon
antibodi
use
determin
exist
immunolog
relat
class
immunotyp
group
virus
defin
abil
neutral
set
monoclon
antibodi
neutrotyp
valu
method
yet
establish
clear
need
polyval
vaccin
absenc
data
support
gener
relev
genotyp
classif
choos
strain
inclus
vaccin
indic
addit
approach
need
pursu
activ
experi
viral
vaccin
use
present
result
extens
studi
siv
shiv
strongli
indic
effect
vaccin
need
induc
broadli
reactiv
neutral
antibodi
cellmedi
immun
potent
broadli
reactiv
neutral
antibodi
describ
studi
sera
subject
studi
neutral
monoclon
antibodi
deriv
cell
individu
therefor
protect
antibodi
repres
human
bcell
repertoir
howev
induc
antibodi
candid
vaccin
proven
difficult
although
broad
rang
antibodi
produc
individu
anim
immun
candid
vaccin
antisera
limit
neutral
activ
measur
either
qualit
quantit
mean
design
new
immunogen
new
approach
might
inform
epitop
describ
target
human
neutral
antibodi
epitop
present
uniqu
challeng
vaccin
design
use
nuanc
pattern
emerg
box
studi
becom
clear
research
past
decad
document
abil
human
immun
system
produc
protect
antibodi
challeng
come
decad
understand
build
immunogen
stimul
b
cell
make
antibodi
